Last reviewed · How we verify
Fostair pMDI
Fostair pMDI is a Small molecule drug developed by Medicines Evaluation Unit Ltd. It is currently FDA-approved.
At a glance
| Generic name | Fostair pMDI |
|---|---|
| Sponsor | Medicines Evaluation Unit Ltd |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study Comparing the Effects of Trimbow to Fostair in COPD (PHASE4)
- Effect of Fostair® on Biomarkers of Platelet Adhesion in Idiopathic Pulmonary Fibrosis (PHASE2)
- Fine Particle pMDI Formoterol/Beclomethasone in Asthmatics With and Without Spacer: Comparative Efficacy Evaluation (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fostair pMDI CI brief — competitive landscape report
- Fostair pMDI updates RSS · CI watch RSS
- Medicines Evaluation Unit Ltd portfolio CI
Frequently asked questions about Fostair pMDI
What is Fostair pMDI?
Fostair pMDI is a Small molecule drug developed by Medicines Evaluation Unit Ltd.
Who makes Fostair pMDI?
Fostair pMDI is developed and marketed by Medicines Evaluation Unit Ltd (see full Medicines Evaluation Unit Ltd pipeline at /company/medicines-evaluation-unit-ltd).
What development phase is Fostair pMDI in?
Fostair pMDI is FDA-approved (marketed).
Related
- Manufacturer: Medicines Evaluation Unit Ltd — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing